Apixaban - Revision history

Danbot: Added AF main page link to See Also

2026-03-25T01:16:01Z

Added AF main page link to See Also

← Revisión anterior		Revisión del 01:16 25 mar 2026
Línea 7:		Línea 7:

	==Adult Dosing==		==Adult Dosing==
	===[[Pulmonary embolism]], [[DVT]]===		===[[Pulmonary embolism]], [[DVT]]===
	*10mg PO twice daily x 7 days, then 5mg BID		*10mg PO twice daily x 7 days, then 5mg BID

Línea 46:		Línea 46:

	==Mechanism of Action==		==Mechanism of Action==
	*Reversible factor Xa inhibitor→ decreased thrombin synthesis		*Reversible factor Xa inhibitor→ decreased thrombin synthesis

	==Comments==		==Comments==


	==Indications by Condition==		==Indications by Condition==
	''The following table is automatically generated from disease/condition pages across WikEM.''		''The following table is automatically generated from disease/condition pages across WikEM.''

	{{#ask:[[Has DrugName::Apixaban]]		{{#ask:[[Has DrugName::Apixaban]]
	\|?Has Indication=Indication		\|?Has Indication=Indication
	\|?Has Dose=Dose		\|?Has Dose=Dose
	\|?Has Context=Context		\|?Has Context=Context
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=table		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50
	}}		}}

Línea 70:		Línea 69:
	*[[Anticoagulant reversal for life-threatening bleeds]]		*[[Anticoagulant reversal for life-threatening bleeds]]
	*[[Procedures in patients with coagulopathies]]		*[[Procedures in patients with coagulopathies]]
			*[[Atrial fibrillation (main)]]
	*[[PE]]		*[[PE]]
	*[[DVT]]		*[[DVT]]
Línea 75:		Línea 75:
	==References==		==References==
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:58:01Z

Switch SMW query from broadtable to table format for better layout with TOC

← Revisión anterior		Revisión del 21:58 20 mar 2026
Línea 59:		Línea 59:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:25:55Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Revisión anterior		Revisión del 17:25 20 mar 2026
Línea 61:		Línea 61:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:44:05Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

@@ Línea 48: / Línea 48: @@
 *Reversible factor Xa inhibitor→ decreased thrombin synthesis
 ==Comments==
 ==See Also==

Rossdonaldson1: /* Adult Dosing */

2023-06-07T22:21:35Z

Adult Dosing

← Revisión anterior		Revisión del 22:21 7 jun 2023
Línea 7:		Línea 7:

	==Adult Dosing==		==Adult Dosing==
	*[[Pulmonary embolism]], [[DVT]]: 10mg PO twice daily x 7 days, then 5mg BID		===[[Pulmonary embolism]], [[DVT]]===
	*Stroke prevention in afib: 5mg PO BID. Reduce the dose to 2.5 mg PO BID if patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.		*10mg PO twice daily x 7 days, then 5mg BID
	*Post-op [[DVT]]prophylaxis after hip or knee arthroplasty: 2.5mg BID
			===Stroke prevention in [[afib]]===
			*5mg PO BID. Reduce the dose to 2.5 mg PO BID if patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.

			===Post-op [[DVT]] prophylaxis after hip or knee arthroplasty===
			*2.5mg BID

	==Pediatric Dosing==		==Pediatric Dosing==

Elcatracho: /* See Also */

2021-02-25T13:42:06Z

Mrosen5506: /* Serious */

2018-08-15T20:15:51Z

Serious

← Revisión anterior		Revisión del 20:15 15 ago 2018
Línea 28:		Línea 28:
	===Serious===		===Serious===
	*Major bleeding (GI, muscular, epidural, intracranial, conjunctival, urinary, intraoperative)		*Major bleeding (GI, muscular, epidural, intracranial, conjunctival, urinary, intraoperative)
			***[[Anticoagulant reversal for life-threatening bleeds\|Bleeding, severe]]
			****[[Andexanet alfa]]
	*LFT abnormalities		*LFT abnormalities

	===Common===		===Common===
	*Easy bruising, hematoma, gingival bleeding, menorrhagia, epistaxis		*Easy bruising, hematoma, gingival bleeding, menorrhagia, epistaxis

Teledoc4u: /* Adult Dosing */

2018-01-16T08:31:52Z

Adult Dosing

← Revisión anterior		Revisión del 08:31 16 ene 2018
Línea 8:		Línea 8:
	==Adult Dosing==		==Adult Dosing==
	*[[Pulmonary embolism]], [[DVT]]: 10mg PO twice daily x 7 days, then 5mg BID		*[[Pulmonary embolism]], [[DVT]]: 10mg PO twice daily x 7 days, then 5mg BID
	*Stroke prevention in afib: 5mg PO BID		*Stroke prevention in afib: 5mg PO BID. Reduce the dose to 2.5 mg PO BID if patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
	*Post-op [[DVT]]prophylaxis after hip or knee arthroplasty: 2.5mg BID		*Post-op [[DVT]]prophylaxis after hip or knee arthroplasty: 2.5mg BID

Humanguy: /* Pharmacology */ added excretion

2017-10-11T20:15:45Z

Pharmacology: added excretion

← Revisión anterior		Revisión del 20:15 11 oct 2017
Línea 35:		Línea 35:
	*Half-life: 7-16 hours		*Half-life: 7-16 hours
	*Metabolism: Hepatic, mainly CYP3A4		*Metabolism: Hepatic, mainly CYP3A4
	*Excretion:		*Excretion: 25% in urine and feces as metabolites; renal excretion accounts for 27%T of total clearance; biliary and direct intestinal excretion contributes to elimination in feces

	==Mechanism of Action==		==Mechanism of Action==

Humanguy: added dosage form, dosage strengths

2017-10-11T20:13:57Z

added dosage form, dosage strengths

← Revisión anterior		Revisión del 20:13 11 oct 2017
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type: [[Anticoagulant]]		*Type: [[Anticoagulant]]
	*Dosage Forms:		*Dosage Forms: tablet
			*Dosage Strengths: 2.5mg, 5mg
	*Routes of Administration: Oral		*Routes of Administration: Oral
	*Common Trade Names: Eliquis		*Common Trade Names: Eliquis

← Revisión anterior		Revisión del 13:42 25 feb 2021
Línea 45:		Línea 45:

	==See Also==		==See Also==
			*[[Andexanet alfa]]
	*[[Anticoagulant reversal for life-threatening bleeds]]		*[[Anticoagulant reversal for life-threatening bleeds]]
	*[[Procedures in patients with coagulopathies]]		*[[Procedures in patients with coagulopathies]]
	*[[PE]]		*[[PE]]
	*[[DVT]]		*[[DVT]]

	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]